For the Inventor, By the Inventor

Enter assignee name

Universite Paris Cité

USPTO Granted Patents = 74

CIPO Patents = 8

EPO Patents = 131

Forward Citations = 6

Loading Chart...

Loading Chart...

287 inventors (with patents filed for the assignee):

Mathieu Pernot (4 out of 28 patents)

Olivier Hermine (3 out of 15 patents)

Thomas Deffieux (3 out of 10 patents)

4. Guido Kroemer (3 out of 17 patents)

5. Marina Cavazzana (3 out of 6 patents)

6. Frank Griscelli (3 out of 4 patents)

7. Annelise Bennaceur Griscelli (3 out of 4 patents)

8. Mickaël Tanter (3 out of 10 patents)

9. Didier Letourneur (2 out of 15 patents)

10. Arnold Munnich (2 out of 12 patents)

11. Christophe Dupont (2 out of 13 patents)

12. Pierre-Henri Benhamou (2 out of 14 patents)

13. Bertrand Dupont (2 out of 14 patents)

14. Vincent Petit (2 out of 7 patents)

15. Alessandro Siria (2 out of 8 patents)

Core Competencies:

Retinal Dystrophies

Cancer Therapy

Biomarkers

Gene Therapy

Microfluidics

Optical Devices

Tissue Engineering

Antibody Development

Signal Processing

Sickle Cell Disease

Neurological Disorders

Cardiac Fibrosis

74 patents: Sort by Forward Citations

1. 12768833 - PROCESS FOR MULTI-ANALYSES OF RARE CELLS EXTRACTED OR ISOLATED FROM BIOLOGICAL SAMPLES THROUGH FILTRATION (2026-10-20),

2. 12758540 - COMPOUND FOR PREVENTING OR TREATING A VIRAL INFECTION (2026-10-13),

3. 12711877 - Apparatus For Simulating An Atonic Uterine Body (2026-08-18),

4. 12678491 - METHODS FOR INDUCING FULL ABLATION OF HEMATOPOIESIS (2026-07-14),

5. 12676451 - Optoelectronic component (2026-07-07),

6. 12673083 - TREM-1 INHIBITORS FOR THE TREATMENT OF VASO-OCCLUSIONS AND TISSUE INJURIES IN PATIENTS SUFFERING FROM SICKLE CELL DISEASE (2026-07-07),

7. 12657499 - Method and device for quantum computing with Majorana modes (2026-06-16),

8. 12644156 - Methods for diagnosing, prognosing and managing treatment of breast cancer (2026-06-02),

9. 12638458 - SERS method for analyzing a viscous biofluid (2026-05-26),

10. 12600966 - METHODS FOR THE TREATMENT OF RETINAL DYSTROPHIES BY EXON-SKIPPING STRATEGY (2026-04-14),

11. 12596125 - Nano-rheological biomarkers for early and improved follow-up of pathologies associated to RBC deformability alteration (2026-04-07),

12. 12591151 - Device for generating single photons and entangled photon pairs (2026-03-31),

13. 12590331 - Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy (2026-03-31),

14. 12590122 - NRP-1 BINDING INHIBITORY PEPTIDES AND USES THEREOF (2026-03-31),

15. 12584165 - Method for Identifying One or More Mutations in a Hotspot Mutation Sequence (2026-03-24),

Company Overview

Université Paris Cité is a prominent institution located in Paris, France, specializing in biomedical innovations. The university focuses on advancing research in critical areas such as retinal dystrophies, cancer therapy, and the development of biomarkers. Its expertise extends to gene therapy, microfluidics, optical devices, tissue engineering, and antibody development. By fostering interdisciplinary collaboration, Université Paris Cité aims to contribute significantly to the medical field and improve patient outcomes through innovative solutions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

74 Patents

#99 in Paris

#350 in France

#10,140 in the World

Universite Paris Cité

Forward Citations = 6

287 inventors:

Mathieu Pernot (4 out of 28 patents)

Olivier Hermine (3 out of 15 patents)

Thomas Deffieux (3 out of 10 patents)

4. Guido Kroemer (3 out of 17 patents)

5. Marina Cavazzana (3 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Universite Paris Cité. Retrieved from https://idiyas.com/company/universite-paris-cite

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…